STRIDES PHARMA SCI LTD is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 3,070 | 3,688 | 4,051 | 4,565 | 4,859 |
| EBITDA (ex other income) | (264) | 413 | 554 | 867 | 898 |
| margin % | (8.6) | 11.2 | 13.7 | 19.0 | 18.5 |
| Owners' profit | (460) | (203) | (71) | 3,593 | 556 |
| EPS, as reported (₹) | (51.28) | (22.49) | (7.76) | 390.54 | 60.34 |
| ROE % · ROCE % | (19.9) · (10.2) | (9.8) · 7.1 | (4.6) · 12.6 | 139.1 · 21.2 | 18.2 · 21.0 |
| Debt / equity (x) | 1.17 | 1.28 | 1.17 | 0.69 | 0.53 |
| Cash from operations | (258) | 44 | 701 | 684 | 703 |
| Capex | (143) | (95) | (118) | (242) | (423) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,201 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 | 1,265 |
| Profit before tax | 128 | 113 | 103 | 122 | 154 | 246 | 147 | 201 |
| Net profit | 94 | 90 | 86 | 106 | 132 | 208 | 129 | 165 |
| EPS (₹) | 10.14 | 9.56 | 8.92 | 10.81 | 13.84 | 21.93 | 13.77 | 17.02 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · USFDA inspection at Alathur facility ends with 3 observations | regulatory legal | medium | — | — |
| 19 Aug 2026 · Strides gets USFDA clearance for Bengaluru plant | business updates | high | — | — |
| 18 Aug 2026 · Strides Pharma AGM: All 6 Resolutions Passed, Dividend Declared | board shareholder meetings | low | — | — |
| 14 Aug 2026 · 35th AGM held on Aug 14, 2026; six resolutions including dividend and director appointments | board shareholder meetings | medium | — | — |
| 3 Aug 2026 · Strides Pharma Q1 FY27: 13% revenue growth, EBITDA margin steady at 18.2% | investor communications | medium | — | — |
| 1 Aug 2026 · Newspaper ad of Q1FY27 unaudited results published | compliance | minimal | — | — |
| 31 Jul 2026 · Earnings call audio for Q1 FY27 results uploaded on website | investor communications | medium | — | — |
| 31 Jul 2026 · Q1FY27: Revenue up 13% YoY at Rs 12,654m; EBITDA margin dips 130bps | investor communications | medium | — | — |
| 31 Jul 2026 · Q1FY27 Results: Revenue Up 13% YoY to Rs 12,654m; EBITDA at Rs 2,298m | results | high | — | — |
| 31 Jul 2026 · Strides Pharma Q1 FY27 PAT up 57% YoY at Rs 165 crore | results | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 18.0 |
| 12.4 |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 17.7 | 28.9 | 50 of 169 | 71% |
| P/B | 3.5 | 3.3 | 87 of 163 | 47% |
| ROCE | 16.6 | 10.8 | 51 of 183 | 73% |
| ROE | 18.2 | 10.4 | 28 of 171 | 84% |
| Debt / Equity | 0.5 | 0.1 | 144 of 171 | 16% |
| EBITDA margin | 23.5 | 17.5 | 59 of 165 | 65% |
| Revenue growth | 13.0 | 16.3 | 85 of 161 | 48% |
| Profit growth | 56.7 | 30.9 | 59 of 158 | 63% |
| Market cap | 10876 | 839 | 43 of 182 | 77% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
